Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Sells $235,443.78 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 1,287 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $182.94, for a total transaction of $235,443.78. Following the transaction, the chief accounting officer directly owned 6,512 shares in the company, valued at approximately $1,191,305.28. The trade was a 16.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Patricia Carr also recently made the following trade(s):

• On Friday, February 27th, Patricia Carr sold 1,117 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $190.91, for a total transaction of $213,246.47.
• On Thursday, February 26th, Patricia Carr sold 1,253 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $194.11, for a total transaction of $243,219.83.

Jazz Pharmaceuticals Stock Up 1.9%

Shares of NASDAQ:JAZZ traded up $3.39 on Monday, reaching $185.40. The company had a trading volume of 715,346 shares, compared to its average volume of 1,102,479. The stock has a market capitalization of $11.41 billion, a P/E ratio of -31.06, a P/E/G ratio of 0.33 and a beta of 0.22. The stock has a 50-day moving average price of $171.11 and a 200 day moving average price of $154.32. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $198.00. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, beating analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The business had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the business earned $6.51 EPS. The firm’s revenue was up 8.1% compared to the same quarter last year. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Farther Finance Advisors LLC increased its stake in Jazz Pharmaceuticals by 754.8% in the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 234 shares during the period. Hilltop National Bank acquired a new stake in Jazz Pharmaceuticals during the fourth quarter valued at approximately $36,000. LRI Investments LLC acquired a new stake in Jazz Pharmaceuticals during the fourth quarter valued at approximately $38,000. Danske Bank A S bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at approximately $40,000. Finally, Quent Capital LLC bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at approximately $44,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Truist Financial increased their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Needham & Company LLC upped their price target on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Bank of America increased their price objective on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Wells Fargo & Company raised their price objective on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Thursday, January 29th. Fourteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $214.57.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.